HomeSGX-LISTED COMPANIESCFM Holdings FY2025 Loss

CFM Holdings FY2025 Loss

Published on

spot_img

CFM Holdings Limited reports a loss after tax for the full year ended 30 June 2025, a notable change from the previous year’s net profit. This downturn is largely due to significantly lower revenue from the metal stamping, components and parts, and cleanroom segments. Contributing factors include customers’ overstocking in the prior period, products reaching their end-of-life cycle, and the maturation of customer contracts. Although the tooling segment saw revenue improvement and the Group achieved lower operational costs and tax expenses, these could not offset the overall impact on profitability.

• Uncover the significant shift in the Group’s financial performance, moving from profit to a substantial loss

• Explore how customer overstocking and product lifecycles profoundly influenced the revenue streams of key business segments

• Learn why, despite efforts to control operational costs, the Group faced a challenging financial year

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...